SENSEX NIFTY
YOU ARE HERE >  Moneycontrol Markets > Announcements Pharmaceuticals

Dr Reddys Laboratories

BSE: 500124|NSE: DRREDDY|ISIN: INE089A01023|SECTOR: Pharmaceuticals
SET ALERT
|
ADD TO PORTFOLIO
|
WATCHLIST
LIVE
BSE
May 04, 11:56
2946.00
-22.25 (-0.75%)
VOLUME 8,520
LIVE
NSE
May 04, 11:56
2944.65
-14.7 (-0.5%)
VOLUME 111,735
Announcements on Dr Reddys Labs

25th-Apr-2016 08:25Source: NSE

Dr. Reddy's Laboratories Limited

Dr. Reddy''s Laboratories Limited has informed the Exchange that, the trading window for dealing in equity shares of the Company will remain closed from April 25, 2016 till May 14, 2016 (both days inc...

24th-Apr-2016 08:25Source: BSE

Dr Reddys Labs- Closure of Trading Window

Dr Reddys Laboratories Ltd has informed BSE that the trading window for dealing in equity shares of the Company will remain closed from Monday, April 25, 2016 till Saturday, May 14, 2016 (both days in...

20th-Apr-2016 08:44Source: BSE

Dr Reddys Labs- FY16 results on May 12, 2016

Dr Reddys Laboratories Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on May 12, 2016, inter alia, to consider and approve the Audited Financial Results of t...

19th-Apr-2016 14:29Source: NSE

Dr. Reddy's Laboratories Limited

Dr. Reddy''s Laboratories Limited has informed the Exchange regarding a press release dated April 19, 2016, titled" ZEMBRACE SymTouch (sumatriptan injection) 3 mg, approved by the FDA in January 2016 ...

19th-Apr-2016 11:38Source: BSE

Dr Reddys Labs- ZEMBRACE™ SymTouch™ (sumatriptan injection) 3 mg, approved by the FDA in January 2016 for the acute treatment of migraine with or without aura in adults, is now commercially available in the U.S.

Dr Reddys Laboratories Ltd has informed BSE regarding a Press Release dated April 19, 2016 titled "ZEMBRACE™ SymTouch™ (sumatriptan injection) 3 mg, approved by the FDA in January 2016 for the acute t...

19th-Apr-2016 11:11Source: BSE

Dr Reddys Labs- Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 for Quarter ended March 31, 2016

Dr Reddys Laboratories Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended March 31, 2016, under Regulation 13(3) of SEBI (...

18th-Apr-2016 09:38Source: NSE

Dr. Reddy's Laboratories Limited

Satish Reddy has submitted to the Exchange vide letter dated April 11, 2016 a copy of disclosure under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2...

12th-Apr-2016 08:39Source: BSE

Dr Reddys Labs- Buy Back Offer

Dr Reddys Laboratories Ltd has informed BSE regarding this Public Announcement ("Public Announcement") is made in relation to the Buyback of equity shares by Dr. Reddy''s Laboratories Limited (the "Co...

7th-Apr-2016 19:07Source: BSE

Dr Reddys Labs- Result of Postal Ballot

Dr Reddys Laboratories Ltd has submitted to BSE a copy of the Special Resolution passed by members of the Company through Postal Ballot.

4th-Apr-2016 08:33Source: NSE

Dr. Reddy's Laboratories Limited

Dr. Reddy''s Laboratories Limited has informed the Exchange regarding the details of Voting results of Postal Ballot along with Scrutinizer''s Reports pursuant to regulation 44 (3) of SEBI (Listing Ob...

1 2 3 4 5 Next >>
Board Meeting (Dr Reddys Labs)

Meeting Date

Remark

2016-05-12

Audited Results & Dividend

Quick Links for Dr Reddys Laboratories
Explore Moneycontrol
Stocks     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | Others
Mutual Funds     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.